The Role of Aldosterone in the Metabolic Syndrome

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2011 Feb 1

PMID 21279740

Citations 35

Authors

Marie Briet

Ernesto L Schiffrin

Affiliations

Soon will be listed here.

Abstract

The metabolic syndrome associates metabolic abnormalities such as insulin resistance and dyslipidemia with increased waist circumference and hypertension. It is a major public health concern, as its prevalence could soon reach 30% to 50% in developed countries. Aldosterone, a mineralocorticoid hormone classically involved in sodium balance regulation, is increased in patients with metabolic syndrome. Besides its classic actions, aldosterone and mineralocorticoid receptor (MR) activation affect glucose metabolism, inducing insulin resistance through various mechanisms that involve oxidative stress, inflammation, and downregulation of proteins involved in insulin signaling pathways. Aldosterone and MR signaling exert deleterious effects on the cardiovascular system and the kidney that influence the cardiovascular risk associated with metabolic syndrome. Salt load plays a major role in cardiovascular injury induced by aldosterone and MR signaling. Large multicenter, randomized clinical trials testing the beneficial effects of MR antagonists on cardiovascular events and mortality in patients with metabolic syndrome are needed.

Citing Articles

Multi-Omic Analysis of the Differences in Growth and Metabolic Mechanisms Between Chinese Domestic Cattle and Simmental Crossbred Cattle.

Wang J, Ni J, Jia X, Sun W, Lai S Int J Mol Sci. 2025; 26(4).

PMID: 40004011 PMC: 11855754. DOI: 10.3390/ijms26041547.

Comparison of echocardiographic findings in patients with aldosterone-producing adenomas: adrenalectomy versus mineralocorticoid receptor antagonists.

Haze T Hypertens Res. 2024; 48(2):816-818.

PMID: 39609647 DOI: 10.1038/s41440-024-02008-8.

Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome.

Singh J, Adel F, Scott C, Chen H Diabetes Obes Metab. 2024; 27(2):777-784.

PMID: 39587371 PMC: 11905735. DOI: 10.1111/dom.16073.

Differences in target organ damage between captopril challenge test-defined definitive-positive and borderline-range groups among patients with primary aldosteronism.

Fujiwara N, Haze T, Wakui H, Tamura K, Tsuiki M, Kamemura K Hypertens Res. 2024; 48(2):540-552.

PMID: 39402300 DOI: 10.1038/s41440-024-01943-w.

Association Between Renal Sinus Fat and Cardiometabolic and Renin-Angiotensin System Parameters in Primary Aldosteronism.

Mitsuno R, Kaneko K, Nakamura T, Kojima D, Mizutani Y, Azegami T J Endocr Soc. 2023; 8(1):bvad154.

PMID: 38116128 PMC: 10729860. DOI: 10.1210/jendso/bvad154.

References

Kraus D, Jager J, Meier B, Fasshauer M, Klein J . Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005; 37(7):455-9. DOI: 10.1055/s-2005-870240. View

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14):1309-21. DOI: 10.1056/NEJMoa030207. View

Goodfriend T, Egan B, Stepniakowski K, Ball D . Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995; 25(1):30-6. DOI: 10.1161/01.hyp.25.1.30. View

Somers M, Mavromatis K, Galis Z, Harrison D . Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000; 101(14):1722-8. DOI: 10.1161/01.cir.101.14.1722. View

Kathiresan S, Larson M, Benjamin E, Corey D, Murabito J, Fox C . Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens. 2005; 18(5 Pt 1):657-65. DOI: 10.1016/j.amjhyper.2004.12.005. View

Matsumoto S, Takebayashi K, Aso Y . The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism. 2006; 55(12):1645-52. DOI: 10.1016/j.metabol.2006.07.025. View

Lakka H, Laaksonen D, Lakka T, Niskanen L, Kumpusalo E, Tuomilehto J . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288(21):2709-16. DOI: 10.1001/jama.288.21.2709. View

Bochud M, Nussberger J, Bovet P, Maillard M, Elston R, Paccaud F . Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006; 48(2):239-45. DOI: 10.1161/01.HYP.0000231338.41548.fc. View

Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M . Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology. 2010; 151(5):2040-9. DOI: 10.1210/en.2009-0869. View

10.

Petrasek D, Jensen G, Tuck M, Stern N . In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci. 1992; 50(23):1781-7. DOI: 10.1016/0024-3205(92)90062-t. View

11.

CONN J . Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med. 1965; 273(21):1135-43. DOI: 10.1056/NEJM196511182732106. View

12.

Eckel R, Alberti K, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2010; 375(9710):181-3. DOI: 10.1016/S0140-6736(09)61794-3. View

13.

Freel E, Tsorlalis I, Lewsey J, Latini R, Maggioni A, Solomon S . Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. Heart. 2009; 95(23):1920-4. DOI: 10.1136/hrt.2009.173344. View

14.

Berg A, Scherer P . Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96(9):939-49. DOI: 10.1161/01.RES.0000163635.62927.34. View

15.

Rossi G, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C . Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008; 93(7):2566-71. DOI: 10.1210/jc.2008-0251. View

16.

Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H . Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and.... Hypertens Res. 2006; 28(11):925-36. DOI: 10.1291/hypres.28.925. View

17.

Mottillo S, Filion K, Genest J, Joseph L, Pilote L, Poirier P . The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56(14):1113-32. DOI: 10.1016/j.jacc.2010.05.034. View

18.

Ammarguellat F, Larouche I, Schiffrin E . Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation. 2001; 103(2):319-24. DOI: 10.1161/01.cir.103.2.319. View

19.

Funder J . Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009; 53(2):286-90. DOI: 10.1161/HYPERTENSIONAHA.108.119966. View

20.

Guo C, Ricchiuti V, Lian B, Yao T, Coutinho P, Romero J . Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008; 117(17):2253-61. PMC: 2746647. DOI: 10.1161/CIRCULATIONAHA.107.748640. View